These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12695337)

  • 21. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
    Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
    Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic Interactions of a Licorice Dietary Supplement with Cytochrome P450 Enzymes in Female Participants.
    Liu J; Banuvar S; Viana M; Barengolts E; Chen SN; Pauli GF; van Breemen RB
    Drug Metab Dispos; 2023 Feb; 51(2):199-204. PubMed ID: 36328482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
    Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
    Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.
    Nyunt MM; Becker S; MacFarland RT; Chee P; Scarborough R; Everts S; Calandra GB; Hendrix CW
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):559-65. PubMed ID: 18362694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers.
    Wong SL; Locke C; Staser J; Granneman GR
    Psychopharmacology (Berl); 1998 Feb; 135(3):236-41. PubMed ID: 9498726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam.
    Yasui-Furukori N; Kondo T; Kubota T; Otake H; Ohkubo T; Nagasaki T; Sugawara K; Chiba K; Otani K; Kaneko S
    Eur J Clin Pharmacol; 2001 Jul; 57(4):285-8. PubMed ID: 11549205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Viloxazine Extended-Release Capsules (Qelbree
    Wang Z; Liranso T; Maldonado-Cruz Z; Kosheleff AR; Nasser A
    Clin Drug Investig; 2024 May; 44(5):303-317. PubMed ID: 38598106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
    Ducharme J; Abdullah S; Wainer IW
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
    DeVane CL; Donovan JL; Liston HL; Markowitz JS; Cheng KT; Risch SC; Willard L
    J Clin Psychopharmacol; 2004 Feb; 24(1):4-10. PubMed ID: 14709940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.
    Wieling J; Tamminga WJ; Sakiman EP; Oosterhuis B; Wemer J; Jonkman JH
    Ther Drug Monit; 2000 Aug; 22(4):486-96. PubMed ID: 10942192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression, purification, and characterization of mouse CYP2d22.
    Yu AM; Haining RL
    Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.